Kawa Chiu
Chief Technical Officer Abdera Therapeutics
Kawa Chiu is the CTO at Abdera Therapeutics, a biopharmaceutical company pioneering precision radiopharmaceuticals through antibody engineering for cancer. Under her leadership, Abdera developed ABD-147 and ABD-320, Actinium-225 therapeutics with companion Indium-111 imaging pairs targeting DLL3 and 5T4-expressing tumors. ABD-147 received FDA Fast Track and Orphan Drug designations in 2024.
Seminars
Thursday 23rd July 2026
Roundtable Discussion: Integrating Radiopharmacies into the Radiotherapy Manufacturing Ecosystem to Expand Reach, Reduce Strain, & Accelerate Patient Access
12:00 pm
- Exploring how leveraging radiopharmacies for therapeutic preparation can extend regional coverage, reduce time-to-treatment for short-lived isotopes, and ease pressure on centralized manufacturing
- Understanding regulatory and operational restrictions in compounding manufacturing and radiopharmacy roles
- Discussing strategic partnerships with national pharmacy networks to improve batch consistency, point-of-care readiness, and public/physician trust in decentralized delivery
Thursday 23rd July 2026
Designing Manufacturing Environments That Enable Compliance, Safety & Sustainability in Therapeutic Radiopharmaceutical Production
Thursday 23rd July 2026
Chair’s Opening Remarks
7:55 am
Thursday 23rd July 2026
Chair’s Closing Remarks
5:00 pm
